Anifrolumab, a relatively new monoclonal antibody, is sparking considerable interest within the medical community as a potential therapy for various immune-related conditions. This distinctive drug targets the IFN https://mediajx.com/story28308411/anifrolumab-a-promising-approach-for-self-reactive-conditions